Low-dose radioiodine therapy for patients with intermediate-to high-risk differentiated thyroid cancer

K Abe, U Ishizaki, T Ono, K Horiuchi, K Kanaya… - Annals of Nuclear …, 2020 - Springer
Objective The efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk
differentiated thyroid cancer (DTC) patients is controversial. Because of the country's …
被引用次数：19 相关文章
[PDF] researchgate.net

[PDF][PDF] Low‑dose radioiodine therapy for patients with intermediate‑to high‑risk differentiated thyroid cancer

K Abe, U Ishizaki, T Ono, K Horiuchi, K Kanaya… - Age, 2019 - researchgate.net
Objective The efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk
differentiated thyroid cancer (DTC) patients is controversial. Because of the country's …

Low-dose radioiodine therapy for patients with intermediate-to high-risk differentiated thyroid cancer.

K Abe, U Ishizaki, T Ono, K Horiuchi… - Annals of Nuclear …, 2019 - europepmc.org
Objective The efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk
differentiated thyroid cancer (DTC) patients is controversial. Because of the country's …

[引用][C] Low-dose radioiodine therapy for patients with intermediate-to high-risk differentiated thyroid cancer

K Abe, U Ishizaki, T Ono, K Horiuchi, K Kanaya… - Annals of Nuclear …, 2019 - cir.nii.ac.jp
Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid
cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Low-dose radioiodine therapy for patients with intermediate-to high-risk differentiated thyroid cancer

K Abe, U Ishizaki, T Ono, K Horiuchi… - Annals of nuclear …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective The efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk
differentiated thyroid cancer (DTC) patients is controversial. Because of the country's …